CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
13. Januar 2025 07:00 ET
|
CytoSorbents
CytoSorbents Strengthens Balance Sheet by $11.25M in Unrestricted Cash through Oversubscribed Shareholder Rights Offering and Satisfied Debt Covenant
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
06. Januar 2025 07:00 ET
|
CytoSorbents
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai, United Arab Emirates, a Gateway to the Middle East and Africa
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
03. Januar 2025 07:00 ET
|
CytoSorbents
CytoSorbents' Preliminary Unaudited Q4 2024 Product Revenue Increased 22-25% From A Year Ago With Product Gross Margins Of ~70%
CytoSorbents Rights Offering Begins
23. Dezember 2024 07:00 ET
|
CytoSorbents
CytoSorbents Rights Offering Begins. Eligible Stockholders are Being Distributed a Dividend of Subscription Rights Based on Shares of CTSO Held.
CytoSorbents Announces Rights Offering
09. Dezember 2024 07:00 ET
|
CytoSorbents
CytoSorbents Announces Rights Offering Exclusive to Stockholders Who Hold or Have Bought CTSO Common Stock by Market Close on Friday, December 13, 2024
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
26. November 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Participate in the Piper Sandler 36th Annual Healthcare Conference. Management holding one-on-one meetings with investors
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
07. November 2024 16:05 ET
|
CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
04. November 2024 07:00 ET
|
CytoSorbents
CytoSorbents submits DrugSorb-ATR Medical Device License Application to Health Canada following MDSAP Certification. Expects regulatory decision in 2025
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
22. Oktober 2024 07:00 ET
|
CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
17. Oktober 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Announce Q3 2024 Financial and Operating Results on November 7, 2024